Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hypertension-Pipeline Review, H1 2015

Hypertension-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hypertension-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hypertension-Pipeline Review, H1 2015', provides an overview of the Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypertension

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hypertension and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hypertension pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hypertension

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 8

Hypertension Overview 9

Therapeutics Development 10

Hypertension-Therapeutics under Development by Companies 12

Hypertension-Therapeutics under Investigation by Universities/Institutes 21

Hypertension-Pipeline Products Glance 24

Hypertension-Products under Development by Companies 28

Hypertension-Products under Investigation by Universities/Institutes 40

Hypertension-Companies Involved in Therapeutics Development 42

Hypertension-Therapeutics Assessment 144

Drug Profiles 163

Hypertension-Recent Pipeline Updates 404

Hypertension-Dormant Projects 463

Hypertension-Discontinued Products 482

Hypertension-Product Development Milestones 485

Appendix 490

List of Tables

Number of Products under Development for Hypertension, H1 2015 31

Number of Products under Development for Hypertension-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 34

Number of Products under Development by Companies, H1 2015 (Contd..1) 35

Number of Products under Development by Companies, H1 2015 (Contd..2) 36

Number of Products under Development by Companies, H1 2015 (Contd..3) 37

Number of Products under Development by Companies, H1 2015 (Contd..4) 38

Number of Products under Development by Companies, H1 2015 (Contd..5) 39

Number of Products under Development by Companies, H1 2015 (Contd..6) 40

Number of Products under Development by Companies, H1 2015 (Contd..7) 41

Number of Products under Investigation by Universities/Institutes, H1 2015 42

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 44

Comparative Analysis by Late Stage Development, H1 2015 45

Comparative Analysis by Clinical Stage Development, H1 2015 46

Comparative Analysis by Early Stage Development, H1 2015 47

Comparative Analysis by Unknown Stage Development, H1 2015 48

Products under Development by Companies, H1 2015 49

Products under Development by Companies, H1 2015 (Contd..1) 50

Products under Development by Companies, H1 2015 (Contd..2) 51

Products under Development by Companies, H1 2015 (Contd..3) 52

Products under Development by Companies, H1 2015 (Contd..4) 53

Products under Development by Companies, H1 2015 (Contd..5) 54

Products under Development by Companies, H1 2015 (Contd..6) 55

Products under Development by Companies, H1 2015 (Contd..7) 56

Products under Development by Companies, H1 2015 (Contd..8) 57

Products under Development by Companies, H1 2015 (Contd..9) 58

Products under Development by Companies, H1 2015 (Contd..10) 59

Products under Development by Companies, H1 2015 (Contd..11) 60

Products under Investigation by Universities/Institutes, H1 2015 61

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 62

Hypertension-Pipeline by A1M Pharma AB, H1 2015 63

Hypertension-Pipeline by AbbVie Inc., H1 2015 64

Hypertension-Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 65

Hypertension-Pipeline by Actelion Ltd, H1 2015 66

Hypertension-Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2015 67

Hypertension-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 68

Hypertension-Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 69

Hypertension-Pipeline by Angion Biomedica Corp., H1 2015 70

Hypertension-Pipeline by APT Therapeutics, Inc., H1 2015 71

Hypertension-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 72

Hypertension-Pipeline by Asahi Kasei Pharma Corp., H1 2015 73

Hypertension-Pipeline by Ascendis Pharma A/S, H1 2015 74

Hypertension-Pipeline by Bayer AG, H1 2015 75

Hypertension-Pipeline by Bial-Portela & Ca, S.A., H1 2015 76

Hypertension-Pipeline by Bio-inRen, H1 2015 77

Hypertension-Pipeline by Biocon Limited, H1 2015 78

Hypertension-Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 79

Hypertension-Pipeline by BioLineRx, Ltd., H1 2015 80

Hypertension-Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2015 81

Hypertension-Pipeline by Carolus Therapeutics, Inc., H1 2015 82

Hypertension-Pipeline by Celladon Corporation, H1 2015 83

Hypertension-Pipeline by Cellceutix Corporation, H1 2015 84

Hypertension-Pipeline by Celsion Corporation, H1 2015 85

Hypertension-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 86

Hypertension-Pipeline by CJ CheilJedang Corp., H1 2015 87

Hypertension-Pipeline by Conatus Pharmaceuticals Inc., H1 2015 88

Hypertension-Pipeline by Corridor Pharmaceuticals Inc., H1 2015 89

Hypertension-Pipeline by Cytokinetics, Inc., H1 2015 90

Hypertension-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 91

Hypertension-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 92

Hypertension-Pipeline by DiaMedica Inc., H1 2015 93

Hypertension-Pipeline by Dong-A Socio Group, H1 2015 94

Hypertension-Pipeline by Eli Lilly and Company, H1 2015 95

Hypertension-Pipeline by Esperion Therapeutics, Inc., H1 2015 96

Hypertension-Pipeline by Galectin Therapeutics, Inc., H1 2015 97

Hypertension-Pipeline by Gilead Sciences, Inc., H1 2015 98

Hypertension-Pipeline by GlaxoSmithKline Plc, H1 2015 99

Hypertension-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 100

Hypertension-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 101

Hypertension-Pipeline by High Point Pharmaceuticals, LLC, H1 2015 102

Hypertension-Pipeline by Innopharmax Inc., H1 2015 103

Hypertension-Pipeline by Insmed Incorporated, H1 2015 104

Hypertension-Pipeline by IntelGenx Corp., H1 2015 105

Hypertension-Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 106

Hypertension-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 107

Hypertension-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 108

Hypertension-Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 109

Hypertension-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 110

Hypertension-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 111

Hypertension-Pipeline by JW Pharmaceutical Corporation, H1 2015 112

Hypertension-Pipeline by Lacer, S.A., H1 2015 113

Hypertension-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 114

Hypertension-Pipeline by Les Laboratoires Servier SAS, H1 2015 115

Hypertension-Pipeline by LG Life Sciences, Ltd., H1 2015 116

Hypertension-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 117

Hypertension-Pipeline by Mallinckrodt Plc, H1 2015 118

Hypertension-Pipeline by Merck & Co., Inc., H1 2015 119

Hypertension-Pipeline by Mezzion Pharma Co. Ltd., H1 2015 120

Hypertension-Pipeline by miRagen Therapeutics, Inc., H1 2015 121

Hypertension-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 122

Hypertension-Pipeline by Neurim Pharmaceuticals Ltd, H1 2015 123

Hypertension-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 124

Hypertension-Pipeline by Nivalis Therapeutics, Inc., H1 2015 125

Hypertension-Pipeline by Novartis AG, H1 2015 126

Hypertension-Pipeline by Noxamet Ltd, H1 2015 127

Hypertension-Pipeline by Omeros Corporation, H1 2015 128

Hypertension-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 129

Hypertension-Pipeline by Peloton Therapeutics, Inc., H1 2015 130

Hypertension-Pipeline by Pfizer Inc., H1 2015 131

Hypertension-Pipeline by PharmaIN Corporation, H1 2015 132

Hypertension-Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 133

Hypertension-Pipeline by Pluristem Therapeutics Inc., H1 2015 134

Hypertension-Pipeline by Proteo, Inc., H1 2015 135

Hypertension-Pipeline by Pulmokine, Inc., H1 2015 136

Hypertension-Pipeline by Quantum Genomics SA, H1 2015 137

Hypertension-Pipeline by Reata Pharmaceuticals, Inc., H1 2015 138

Hypertension-Pipeline by RedHill Biopharma Ltd., H1 2015 139

Hypertension-Pipeline by Respira Therapeutics, Inc., H1 2015 140

Hypertension-Pipeline by rEVO Biologics, Inc., H1 2015 141

Hypertension-Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 142

Hypertension-Pipeline by Sanofi, H1 2015 143

Hypertension-Pipeline by Serodus ASA, H1 2015 144

Hypertension-Pipeline by Silence Therapeutics Plc, H1 2015 145

Hypertension-Pipeline by Simcere Pharmaceutical Group, H1 2015 146

Hypertension-Pipeline by Sinoxa Pharma GmbH, H1 2015 147

Hypertension-Pipeline by SteadyMed Therapeutics, Inc., H1 2015 148

Hypertension-Pipeline by Suda Ltd, H1 2015 149

Hypertension-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 150

Hypertension-Pipeline by Symplmed, Inc., H1 2015 151

Hypertension-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 152

Hypertension-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 153

Hypertension-Pipeline by The Medicines Company, H1 2015 154

Hypertension-Pipeline by Toray Industries, Inc., H1 2015 155

Hypertension-Pipeline by Torrent Pharmaceuticals Limited, H1 2015 156

Hypertension-Pipeline by TSH Biopharm Corporation Limited, H1 2015 157

Hypertension-Pipeline by vasopharm GmbH, H1 2015 158

Hypertension-Pipeline by VBS Pharmaceuticals, H1 2015 159

Hypertension-Pipeline by Vectura Group Plc, H1 2015 160

Hypertension-Pipeline by VG Life Sciences, Inc., H1 2015 161

Hypertension-Pipeline by Vicore Pharma AB, H1 2015 162

Hypertension-Pipeline by Yuhan Corporation, H1 2015 163

Hypertension-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 164

Assessment by Monotherapy Products, H1 2015 165

Assessment by Combination Products, H1 2015 166

Number of Products by Stage and Target, H1 2015 168

Number of Products by Stage and Mechanism of Action, H1 2015 175

Number of Products by Stage and Route of Administration, H1 2015 181

Number of Products by Stage and Molecule Type, H1 2015 183

Hypertension Therapeutics-Recent Pipeline Updates, H1 2015 425

Hypertension-Dormant Projects, H1 2015 484

Hypertension-Dormant Projects (Contd..1), H1 2015 485

Hypertension-Dormant Projects (Contd..2), H1 2015 486

Hypertension-Dormant Projects (Contd..3), H1 2015 487

Hypertension-Dormant Projects (Contd..4), H1 2015 488

Hypertension-Dormant Projects (Contd..5), H1 2015 489

Hypertension-Dormant Projects (Contd..6), H1 2015 490

Hypertension-Dormant Projects (Contd..7), H1 2015 491

Hypertension-Dormant Projects (Contd..8), H1 2015 492

Hypertension-Dormant Projects (Contd..9), H1 2015 493

Hypertension-Dormant Projects (Contd..10), H1 2015 494

Hypertension-Dormant Projects (Contd..11), H1 2015 495

Hypertension-Dormant Projects (Contd..12), H1 2015 496

Hypertension-Dormant Projects (Contd..13), H1 2015 497

Hypertension-Dormant Projects (Contd..14), H1 2015 498

Hypertension-Dormant Projects (Contd..15), H1 2015 499

Hypertension-Dormant Projects (Contd..16), H1 2015 500

Hypertension-Dormant Projects (Contd..17), H1 2015 501

Hypertension-Dormant Projects (Contd..18), H1 2015 502

Hypertension-Discontinued Products, H1 2015 503

Hypertension-Discontinued Products (Contd..1), H1 2015 504

Hypertension-Discontinued Products (Contd..2), H1 2015 505

List of Figures

Number of Products under Development for Hypertension, H1 2015 31

Number of Products under Development for Hypertension-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 33

Number of Products under Investigation by Universities/Institutes, H1 2015 42

Comparative Analysis by Late Stage Development, H1 2015 45

Comparative Analysis by Clinical Stage Development, H1 2015 46

Comparative Analysis by Early Stage Products, H1 2015 47

Assessment by Monotherapy Products, H1 2015 165

Assessment by Combination Products, H1 2015 166

Number of Products by Top 10 Targets, H1 2015 167

Number of Products by Stage and Top 10 Targets, H1 2015 167

Number of Products by Top 10 Mechanism of Actions, H1 2015 174

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 174

Number of Products by Top 10 Routes of Administration, H1 2015 180

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 180

Number of Products by Top 10 Molecule Types, H1 2015 182

Number of Products by Stage and Top 10 Molecule Types, H1 2015 182

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

A1M Pharma AB

AbbVie Inc.

Ache Laboratorios Farmaceuticos S/A

Actelion Ltd

Ahn-Gook Pharmaceutical Co., Ltd.

Alnylam Pharmaceuticals, Inc.

Anacor Pharmaceuticals, Inc.

Angion Biomedica Corp.

APT Therapeutics, Inc.

Arena Pharmaceuticals, Inc.

Asahi Kasei Pharma Corp.

Ascendis Pharma A/S

Bayer AG

Bial - Portela & Ca, S.A.

Bio-inRen

Biocon Limited

Biolab Sanus Farmaceutica Ltda.

BioLineRx, Ltd.

Cardioxyl Pharmaceuticals, Inc.

Carolus Therapeutics, Inc.

Celladon Corporation

Cellceutix Corporation

Celsion Corporation

Chong Kun Dang Pharmaceutical Corp.

CJ CheilJedang Corp.

Conatus Pharmaceuticals Inc.

Corridor Pharmaceuticals Inc.

Cytokinetics, Inc.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

DiaMedica Inc.

Dong-A Socio Group

Eli Lilly and Company

Esperion Therapeutics, Inc.

Galectin Therapeutics, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

High Point Pharmaceuticals, LLC

Innopharmax Inc.

Insmed Incorporated

IntelGenx Corp.

Intercept Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

Jeil Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

JW Pharmaceutical Corporation

Lacer, S.A.

Lee's Pharmaceutical Holdings Limited

Les Laboratoires Servier SAS

LG Life Sciences, Ltd.

LTT Bio-Pharma Co., Ltd.

Mallinckrodt Plc

Merck & Co., Inc.

Mezzion Pharma Co. Ltd.

miRagen Therapeutics, Inc.

Mitsubishi Tanabe Pharma Corporation

Neurim Pharmaceuticals Ltd

Nippon Shinyaku Co., Ltd.

Nivalis Therapeutics, Inc.

Novartis AG

Noxamet Ltd

Omeros Corporation

Ono Pharmaceutical Co., Ltd.

Peloton Therapeutics, Inc.

Pfizer Inc.

PharmaIN Corporation

PhaseBio Pharmaceuticals, Inc.

Pluristem Therapeutics Inc.

Proteo, Inc.

Pulmokine, Inc.

Quantum Genomics SA

Reata Pharmaceuticals, Inc.

RedHill Biopharma Ltd.

Respira Therapeutics, Inc.

rEVO Biologics, Inc.

Sagene Pharmaceuticals, Inc.

Sanofi

Serodus ASA

Silence Therapeutics Plc

Simcere Pharmaceutical Group

Sinoxa Pharma GmbH

SteadyMed Therapeutics, Inc.

Suda Ltd

Sun Pharma Advanced Research Company Ltd.

Symplmed, Inc.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Limited

The Medicines Company

Toray Industries, Inc.

Torrent Pharmaceuticals Limited

TSH Biopharm Corporation Limited

vasopharm GmbH

VBS Pharmaceuticals

Vectura Group Plc

VG Life Sciences, Inc.

Vicore Pharma AB

Yuhan Corporation

Yungjin Pharm Ind. Co., Ltd.

Hypertension Therapeutic Products under Development, Key Players in Hypertension Therapeutics, Hypertension Pipeline Overview, Hypertension Pipeline, Hypertension Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com